CAS No. :4682-36-4 Name :Orphenadrine citrate Synonyms::beta-dimethylaminoethyl 2-methylbenzhydryl ether citrate;BETA-DIMETHYLAMINOETHYL 2-METHYLBENZHYDRYL ETHER CITRATE SALT;o-methyldiphenhydramine citrate;ORPHENADRINE CITRATE SALT;orphenadrine dihydrogen citrate;Banflex;N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy] ethanamine Citrate Salt;X-Ota Molecular Formula:C24H31NO8 Molecular Weight::461.5 Wiki: Orphenadrine Systematic (IUPAC) name N,N -dimethyl-2-[(2-methylphenyl)- phenyl-methoxy]-ethanamine Clinical data Trade names Invagesic AHFS/Drugs.com monograph MedlinePlus a682162 Pregnancy cat. B2 (AU) C (US) Legal status Prescription Only (S4) (AU) OTC (CA) POM (UK) â„ž-only (US) Routes Oral, intravenous, intramuscular Pharmacokinetic data Bioavailability 90% Protein binding 95% Metabolism Hepatic demethylation Half-life 13-20 hours[1] Excretion Renal and biliary Identifiers CAS number 83-98-7Â Y ATC code M03BC01 N04AB02 PubChem CID 4601 DrugBank DB01173 ChemSpider 4440Â Y UNII AL805O9OG9Â Y KEGG D08305Â Y ChEBI CHEBI:7789Â Y ChEMBL CHEMBL900Â Y Chemical data Formula C18H23NOÂ Mol. mass 269.381 g/mol SMILES O(CCN(C)C)C(c1ccccc1)c2ccccc2C InChI InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-1 0-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3Â Y Key:QVYRGXJJSLMXQH-UHFFFAOYSA-NÂ Y Â YÂ (what is this?)Â Â (verify) Orphenadrine (sold under the brand names: Norflex, Mephenamin, Disipal, Banflex, Flexon, Biorphen, Brocasipal, Dolan, Norgesic, OrfenAce and others) is an anticholinergic drug of the ethanolamine antihistamine class with prominent CNS and peripheral actions used to treat painful muscle spasms, other similar conditions, as well as the treatment of some aspects of Parkinson's Disease. It is closely related to diphenhydramine. Therefore, it is related to other drugs used for Parkinson's like benztropine and trihexyphenidyl, and it is also structurally related to nefopam,[2] which is a centrally-acting yet non-opioid analgesic. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including pain from: radiculopathy, muscle pain, and headaches[ citation needed]. Orphenadrine has approximately 58% of the anticholinergic potency of atropine at equivalent doses. Orphenadrine is most often used against pain and muscle spasm of various etiologies including lumbago, sciatica, and injury. It is quite useful against allergic symptoms and other histamine-related effects, such as those from hay fever, other allergies, and histamine release from many opioid analgesics. Where available for prescription compounding, orphenadrine can also be prepared for topical administration and works slightly better than diphenhydramine for this purpose. The orphenadrine salt used for Parkinsonism is the hydrochloride, whereas the muscle relaxant tablets are the citrate.
The manufacturers' descriptions of orphenadrine indicate that the salts are not interchangeable; one reason may be that the citrate can be irritating when injected. Euphoria is an effect reported by many patients and orphenadrine has been investigated for use against depression, as first reported in June 1958 in the American Journal of Psychiatry.[3] Like many first-generation antihistamines and chemically-similar anticholinergics, orphenadrine can also cause excitement and insomnia, particularly in children and the elderly. Orphenadrine also works on smooth muscle in a manner identical to that of dicyclomine, brand name Bentyl, and will impact Irritable Bowel Syndrome in a similar fashion. Safety Statements:22-36 ;
THE 2th , THE WHOLE 2th AND NOTHING BUT THE 2th compiled by Leslie Lang 8 Ohlsson Way, Newlands, 7700 Tel 683 0533 Housekeeping Notes • While we realize that there is abundant parking in the road outside our premises, we should really appreciate it if you could park inside the property to avoid any inconvenience to the neighbours. • Please remember that I am always available
North Carolina Department of Health and Human Services VIA EMAIL Lorraine Cummings, MD, Owner FEMCARE, Inc. 62 Orange Street Asheville, NC 28801 Dear Dr. Cummings: Thank you for the opportunity to discuss the re-opening of FEMCARE, Inc. upon the remedies put in place to correct the deficiencies found in the July 19, 2013 survey. I feel obligated to continue this dialogue by clarifying a statem